Lymphoma, Large B-Cell, Diffuse Archives | MSD Oncology Clinical Trials

Study Keyword: Lymphoma, Large B-Cell, Diffuse

This study consists of a dose escalation/confirmation phase and an efficacy expansion phase. The dose escalation/confirmation phase is to determine the safety and tolerability and establish a preliminary recommended Phase 2 dose (RP2D) of zilovertamab vedotin when administered in combination with R-CHP in participants with DLBCL who have received no prior treatment for their disease. The efficacy expansion phase is to determine the efficacy of the RP2D of zilovertamab vedotin when administered in combination with R-CHP in participants with DLBCL who have received no prior treatment for their disease.

A Study of Zilovertamab Vedotin in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar in Participants With Diffuse Large B-Cell Lymphoma

September 1, 2022

By Tyler Kalist

A Study to Evaluate Zilovertamab Vedotin for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

March 10, 2022

By Tyler Kalist

The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review

A Study of Zilovertamab Vedotin in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

March 10, 2022

By Support_Clique

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care